Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy

Authors: Nicole Lamanna, Constantine S. Tam, Jennifer A. Woyach, Alvaro J. Alencar, M. Lia Palomba, Pier Luigi Zinzani, Ian W. Flinn, Bita Fakhri, Jonathon B. Cohen, Arrin Kontos, Heiko Konig, Amy S. Ruppert, Anindya Chatterjee, Richard Sizelove, Livia Compte, Donald E. Tsai, Wojciech Jurczak

Source: eJHaem, Vol 5, Iss 5, Pp 929-939 (2024)

Subject Terms: antithrombotic therapy, B‐cell cancers, bleeding, Bruton tyrosine kinase inhibitor, pirtobrutinib, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/82cd9c8755ab4351873ea8a263b45176

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report

Authors: Anna Nikkarinen, Ingrid Glimelius

Source: eJHaem, Vol 5, Iss 4, Pp 820-824 (2024)

Subject Terms: acalabrutinib, aplastic anemia, Bruton tyrosine kinase inhibitor, case report, mantle cell lymphoma, pancytopenia, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/50b4c284d8bc4181b61e6221f4fd7b3c

Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis

Authors: Jaradat, Jaber H. ^{a, 1}, Alkhawaldeh, Ibraheem M. ^{a, 2}, Al-Bojoq, Yousef ^{a, 3}, Ramadan, Monther N. ^{a, 4}, Abuawwad, Mohammad T. ^{b, 5}, Alabdallat, Yasmeen Jamal ^{c, 6}, Nashwan, Abdulqadir J. ^{d, ⁎, 7}

Source: In Critical Reviews in Oncology / Hematology February 2025 206

Fungal infection in patients treated with Bruton tyrosine kinase inhibitor—from epidemiology to clinical outcome: a systematic review

Authors: Gibert, Charles ^{1, 2}, Blaize, Marion ³, Fekkar, Arnaud ^{3, ⁎}

Source: In Clinical Microbiology and Infection December 2024

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies

Authors: Benjamin J. Lee, Jenny Liu, Shawn P. Griffin, Jean Doh, Stefan O. Ciurea, Piyanuch Kongtim, Elizabeth A. Brem

Source: Cancer Medicine, Vol 13, Iss 19, Pp n/a-n/a (2024)

Subject Terms: blastoid variant, Bruton tyrosine kinase inhibitor, mantle cell lymphoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/f32d25f161b540169020aab4f31e69f2

Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft

Authors: Louis Stavart, Matthieu Halfon, Natacha Dewarrat, Samuel Rotman, Dela Golshayan

Source: Frontiers in Medicine, Vol 11 (2024)

Subject Terms: chronic lymphocytic leukemia, kidney transplantation, Bruton tyrosine kinase inhibitor, acute cellular rejection, case report, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fmed.2024.1451264/full; https://doaj.org/toc/2296-858X

Access URL: https://doaj.org/article/4bb8a75ea8b84e939b3f2a039186aa7c

Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis

Authors: Liyuan Ke, Su Li, Danxue Huang, Yan Wang

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: Bruton tyrosine kinase inhibitor, chronic lymphocytic leukemia, efficacy, safety, meta-analysis, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1413985/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/b850ebe9fd69441fa7931008fc975011

Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report

Authors: Ying Zhou, Xiaoxue Wang, Xuyong Lin, Jun Wang, Xiaojing Yan, Ying Wen

Source: AIDS Research and Therapy, Vol 20, Iss 1, Pp 1-5 (2023)

Subject Terms: Primary central nervous system lymphoma, Human immunodeficiency virus, Bruton tyrosine kinase inhibitor, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://doaj.org/toc/1742-6405

Access URL: https://doaj.org/article/40a30e66ce484da790091052d8194380

Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS: In vitro and in silico metabolic study

Authors: Alsibaee, Aishah M. ^∗, Aljohar, Haya I., Attwa, Mohamed W., Abdelhameed, Ali Saber, Kadi, Adnan A.

Source: In Heliyon June 2023 9(6)

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First

Authors: Deshpande A, Munoz J

Source: Therapeutics and Clinical Risk Management, Vol Volume 18, Pp 657-668 (2022)

Subject Terms: zanubrutinib, waldenstrom macroglobulinemia, bruton tyrosine kinase inhibitor, ibrutinib, rituximab, efficacy, safety, atrial fibrillation, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.dovepress.com/zanubrutinib-in-treating-waldenstrm-macroglobulinemia-the-last-shall-b-peer-reviewed-fulltext-article-TCRM; https://doaj.org/toc/1178-203X

Access URL: https://doaj.org/article/3cd502f03fb343309af143060d75c8fc

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review

Authors: Gaurav Nepal, Mahika Khurana, Domenica Herrera Bucheli, Siddhartha Bhandari, Utsav Joshi, Riwaj Bhagat, Jessica Holly Rehrig, Prasun Pudasainee, Yow Ka Shing, Juan Fernando Ortiz, Rajeev Ojha, Bikram Prasad Gajurel, Jonathan Quinonez, Samir Ruxmohan, Trevine Albert, Steven Licata, Joel Stien

Source: Neurology International, Vol 14, Iss 1, Pp 99-108 (2022)

Subject Terms: ibrutinib, BTK, Bruton tyrosine kinase inhibitor, PCNSL, primary central nervous system lymphoma, lymphoma, Medicine, Internal medicine, RC31-1245, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571

File Description: electronic resource

Relation: https://www.mdpi.com/2035-8377/14/1/9; https://doaj.org/toc/2035-8377

Access URL: https://doaj.org/article/47ef347b78db4bdc988035daef4bcf49

Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders

Authors: Saadia Sherazi, Susan Schleede, Scott McNitt, Carla Casulo, Jeremiah E. Moore, Eugene Storozynsky, Arpan Patel, Neelima Vidula, Mehmet K. Aktas, Clive S. Zent, Ilan Goldenberg

Source: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 6 (2023)

Subject Terms: arrhythmia, Bruton tyrosine kinase inhibitor, cardiotoxicity, ibrutinib, lymphoma, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/2047-9980

Access URL: https://doaj.org/article/90fe15e8420a4bfab40bc8345039f481

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy

Authors: Ying Ni, Lixia Gao, Yan Lu, Shiguang Ye, Lili Zhou, Wenbin Qian, Aibin Liang, Ping Li

Source: Frontiers in Immunology, Vol 13 (2022)

Subject Terms: HBV reactivation, diffuse large B-cell lymphoma, Bruton tyrosine kinase inhibitor, resolved HBV infection, prognosis, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.982346/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/79870a56710042e590c4dcd046294d01

Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome

Authors: Yuehua Huang, Yanying Wang, Fan Yu, Xuehan Mao, Bianhong Wang, Jingxian Li, Lihong Li

Source: Frontiers in Immunology, Vol 13 (2022)

Subject Terms: Schnitzler syndrome, interleukin-1, Bruton tyrosine kinase inhibitor, ibrutinib, case report, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.894464/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/886f06da3c07408386d231b9d19cd36b

Investigation of Fenebrutinib Metabolism and Bioactivation Using MS3 Methodology in Ion Trap LC/MS

Authors: Aishah M. Alsibaee, Haya I. Aljohar, Mohamed W. Attwa, Ali S. Abdelhameed, Adnan A. Kadi

Source: Molecules, Vol 28, Iss 10, p 4225 (2023)

Subject Terms: fenebrutinib, Bruton tyrosine kinase inhibitor, metabolism, reactive intermediates, trapping agents, LC-ITMS, Organic chemistry, QD241-441

File Description: electronic resource

Relation: https://www.mdpi.com/1420-3049/28/10/4225; https://doaj.org/toc/1420-3049

Access URL: https://doaj.org/article/89e56f63b2aa4f13b9ab39b31de340e9

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib

Authors: Xiao Zhang, Rongping Dai, Chan Zhao, Meifen Zhang

Source: Frontiers in Medicine, Vol 9 (2022)

Subject Terms: primary vitreoretinal lymphoma, intraocular hemorrhage, zanubrutinib, bruton tyrosine kinase inhibitor, intravitreal injection, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fmed.2022.833565/full; https://doaj.org/toc/2296-858X

Access URL: https://doaj.org/article/5cb1f46e8e3d43f68a7253bc91163ae3

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review

Authors: Mitra Rezaei, MD, Saghar Barati, Pharm-D, PhD, Abdolreza Babamahmoodi, MD, Farzaneh Dastan, Pharm-D, PhD, Majid Marjani, MD

Source: Current Therapeutic Research, Vol 96, Iss , Pp 100658- (2022)

Subject Terms: Bruton tyrosine kinase inhibitor, COVID-19, SARS-CoV-2, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0011393X21000369; https://doaj.org/toc/0011-393X

Access URL: https://doaj.org/article/f2ae85bbf17d4b558f2246bf70dc9b5e

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

Authors: Ana-Maria Moldovianu, Razvan Stoia, Mariana Vasilica, Iulia Ursuleac, Sorina Nicoleta Badelita, Andra Alina Tomescu, Oana Diana Preda, Alexandru Bardas, Mihaela Cirstea, Daniel Coriu

Source: Medicina, Vol 59, Iss 2, p 324 (2023)

Subject Terms: chronic lymphocytic leukemia (CLL), ibrutinib, real-world, Bruton tyrosine kinase inhibitor, adverse events, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.mdpi.com/1648-9144/59/2/324; https://doaj.org/toc/1010-660X; https://doaj.org/toc/1648-9144

Access URL: https://doaj.org/article/a97696fe68444e3e966c3c05b65ac7a5

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Authors: Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda

Source: Frontiers in Oncology, Vol 11 (2021)

Subject Terms: acalabrutinib, adverse events, Bruton tyrosine kinase inhibitor, chronic lymphocytic leukemia, ibrutinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.720704/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55

Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia

Authors: Javier Muñoz, Jonas Paludo, Shayna Sarosiek, Jorge J. Castillo

Source: Cells, Vol 11, Iss 20, p 3287 (2022)

Subject Terms: Waldenström macroglobulinemia, zanubrutinib, Bruton tyrosine kinase inhibitor, costs, combination therapy, Cytology, QH573-671

File Description: electronic resource

Relation: https://www.mdpi.com/2073-4409/11/20/3287; https://doaj.org/toc/2073-4409

Access URL: https://doaj.org/article/c35a680c724548dcabf7bcb146ae249b